Which symptoms predict recurrence of depression in women treated with maintenance interpersonal psychotherapy?
BACKGROUND
Even low levels of residual symptoms are known to increase the risk of relapse and early recurrence of major depression. It is not known if ongoing psychotherapy lessens this risk. We therefore examined the impact of persistent symptoms, including mood, insomnia, and anxiety symptoms, on time to recurrence in women receiving maintenance interpersonal psychotherapy (IPT-M) for recurrent depression.


METHODS
We analyzed data on 131 women aged 20-60 from a 2-year randomized trial of weekly versus twice-monthly versus monthly IPT-M. Participants achieved remission with IPT alone (n=99) or IPT plus sequential antidepressant medication (n=32). Medications were tapered before starting maintenance treatment. Residual symptoms were assessed with the Hamilton Rating Scale for Depression (HRSD; total score and subscales); insomnia was also assessed in 76 women with the Pittsburgh Sleep Quality Index (PSQI). Data analyses used Cox proportional hazards regression models.


RESULTS
Neither overall burden of residual symptoms (HRSD total score), nor HRSD mood and anxiety subscale scores predicted recurrence during ongoing IPT-M. In contrast, persistent insomnia measured both by the HRSD-17 insomnia subscale and the PSQI predicted recurrence. Women with persistent insomnia who required sequential pharamacotherapy had the highest recurrence rate (65%) compared to women requiring sequential treatment without insomnia (13%), or women who had recovered with IPT alone but had persistent insomnia (21%) or no insomnia (18%).


CONCLUSIONS
Persistent insomnia following the recovery from an episode of recurrent major depression is associated with increased risk of recurrence despite maintenance psychotherapy, particularly for those withdrawn from antidepressant medication.
Dombrovski
Alexandre Y
AY
Western Psychiatric Institute and Clinic, Department of Psychiatry, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, USA.
Cyranowski
Jill M
JM
Mulsant
Benoit H
BH
Houck
Patricia R
PR
Buysse
Daniel J
DJ
Andreescu
Carmen
C
Thase
Michael E
ME
Mallinger
Alan G
AG
Frank
Ellen
E
D000328:Adult; D000339:Affect; D001008:Anxiety Disorders / Q000175:diagnosis / Q000523:psychology / Q000628:therapy; D003131:Combined Modality Therapy; D015897:Comorbidity; D003865:Major Depressive Disorder / Q000175:diagnosis / Q000523:psychology / Q000628:therapy*; D005260:Female; D006801:Humans; D008875:Middle Aged; D010552:Personality Assessment / Q000706:statistics & numerical data; D011594:Psychometrics; D011613:Psychotherapy / Q000379:methods*; D011725:Pyridines / Q000627:therapeutic use; D012008:Recurrence; D018570:Risk Assessment; D017367:Selective Serotonin Reuptake Inhibitors / Q000627:therapeutic use; D007319:Sleep Initiation and Maintenance Disorders / Q000523:psychology / Q000628:therapy; D014196:Trazodone / Q000627:therapeutic use; D055815:Young Adult; D000077334:Zolpidem
D011725:Pyridines; D017367:Selective Serotonin Reuptake Inhibitors; D014196:Trazodone; D000077334:Zolpidem
Sleep. 2001 Feb 1;24(1):110-7
11204046
Am J Psychiatry. 2007 May;164(5):761-7
17475735
Acta Psychiatr Scand. 1978 Mar;57(3):193-201
347885
Int J Neuropsychopharmacol. 2007 Oct;10(5):661-73
17477888
Psychiatry Res. 1997 Jan 15;66(1):23-31
9061801
Acta Psychiatr Scand Suppl. 2007;(433):104-15
17280576
Psychol Aging. 2000 Jun;15(2):232-40
10879578
Neurosci Lett. 2002 May 17;324(2):159-63
11988351
Behav Ther. 2007 Mar;38(1):49-57
17292694
Psychol Med. 1999 Jan;29(1):47-61
10077293
J Clin Psychiatry. 2007 Feb;68(2):254-60
17335324
Gen Hosp Psychiatry. 1997 Jul;19(4):245-50
9327253
J Clin Psychol. 2006 Jan;62(1):123-46
16287149
Sleep. 2002 Sep 15;25(6):630-40
12224842
Psychiatry Res. 1989 May;28(2):193-213
2748771
BMC Psychiatry. 2007 Aug 21;7:42
17711589
Sleep. 2003 Mar 15;26(2):130-6
12683470
J Nerv Ment Dis. 1975 Jan;160(1):24-33
1113090
Am J Psychiatry. 1996 Nov;153(11):1404-10
8890672
J Affect Disord. 1998 Sep;50(2-3):97-108
9858069
Am J Psychiatry. 2000 Jul;157(7):1101-7
10873918
Biol Psychiatry. 2006 Jun 1;59(11):1052-60
16581036
Neuropsychopharmacology. 1996 Apr;14(4):243-52
8924192
J Clin Psychiatry. 2002 Jun;63(6):493-500
12088160
Am J Psychiatry. 1992 Aug;149(8):1046-52
1636804
Am J Psychiatry. 2004 Dec;161(12):2163-77
15569884
J Neurol Neurosurg Psychiatry. 1960 Feb;23:56-62
14399272
Eur Neuropsychopharmacol. 2006 Feb;16(2):93-100
16249073
J Clin Psychiatry. 1982 Sep;43(9):366-8
7118845
Br Med J. 1976 May 8;1(6018):1116-8
773506
Int Clin Psychopharmacol. 2002 Sep;17(5):239-47
12177586
Psychol Med. 1998 May;28(3):731-5
9626729
Arch Intern Med. 2004 Sep 27;164(17):1888-96
15451764
Psychol Med. 2003 Jul;33(5):839-45
12877398
Sleep. 2007 Jul;30(7):873-80
17682658
J Clin Psychiatry. 2001 Jun;62(6):453-63
11465523
Psychopharmacology (Berl). 1985;85(1):14-22
3920695
Electroencephalogr Clin Neurophysiol. 1997 May;102(5):390-6
9191582
J Clin Psychiatry. 1999 Oct;60(10):668-76
10549683
JAMA. 2006 Jun 28;295(24):2851-8
16804151
Am J Psychiatry. 2004 Nov;161(11):2126-8
15514418
J Psychiatr Res. 2006 Dec;40(8):700-8
16978649
J Affect Disord. 2003 Sep;76(1-3):255-9
12943956
J Affect Disord. 2007 Nov;103(1-3):77-82
17321595
Am J Psychiatry. 1997 Jul;154(7):958-62
9210746
Eur J Neurosci. 1998 May;10(5):1826-34
9751153
Sleep. 1995 Sep;18(7):581-8
8552929
Am J Psychiatry. 2004 Oct;161(10):1877-84
15465986
Arch Gen Psychiatry. 1990 Dec;47(12):1100-5
2244794
Psychol Med. 1995 Nov;25(6):1171-80
8637947
J Affect Disord. 1997 Feb;42(2-3):209-12
9105962
Am J Geriatr Psychiatry. 2006 Jun;14(6):550-4
16731725
J Clin Endocrinol Metab. 2001 Aug;86(8):3787-94
11502812
Arch Gen Psychiatry. 1996 Feb;53(2):99-108
8629894
J Affect Disord. 1992 Mar;24(3):135-45
1573122